<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367587</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 253</org_study_id>
    <nct_id>NCT01367587</nct_id>
  </id_info>
  <brief_title>Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone</brief_title>
  <official_title>Safety and Gastrointestinal Effects of Multiple-Dosed Intravenous Methylnaltrexone in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety of multiple doses of IV MNTX in normal healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">July 2002</completion_date>
  <primary_completion_date type="Actual">July 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve (AUC) of IV MNTX</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of IV MNTX Excreted in Urine</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate plasma pharmacokinetics of multiple-doses of intravenous methylnaltrexone in healthy human volunteers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Methylnaltrexone</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be male or non-pregnant female volunteers

          2. Must be 18 to 65 yrs of age

          3. Must have no significant active disease states

        Exclusion Criteria:

          1. History or current evidence of disease (cardiovascular, respiratory, endocrine, renal,
             hepatic, hematological, or psychiatric)

          2. Illicit drug users

          3. Subjects who received an experimental new drug in the past 30 days

          4. Subjects with any laboratory findings outside normal limits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, MD</name_title>
    <organization>Progenics Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

